Clinical Cancer Genomics conference, March 20-21 2025, Amsterdam
We are pleased to announce that registration for this novel exciting meeting focused on cancer whole genome and transcriptome sequencing in a clinical setting, is now open. Please visit www.ccg2025.eu for more information, abstract submission or registration of your participation!
An increasing number of European countries are adapting clinical cancer (gen)omics programs including whole genome and transcriptome sequencing (WGTS) to enable cancer precision medicine and support research and a learning health care system for improving future cancer care.
This meeting will be the first of an annual recurring series and aims to bring together researchers and medical specialists involved in these programs or interested in genomics-based and data-driven cancer care and/or research. The current state-of-the-art implementations in routine care, research highlights, clinical impact and future developments will be presented and discussed.
National programs in Europe supporting translation of genomics approaches from the clinic to research and back will be central to this meeting. The first meeting will take place on Thursday March 20 and Friday 21, 2025 in Amsterdam, the Netherlands, and is initiated as part of the 10th anniversary of Hartwig Medical Foundation. The meeting will be organised together with Genomics England, DKFZ German Cancer Research Center MASTER/NCT, Genomic Medicine Sweden, Plan France Médecine Génomique 2025 , and Danish National Genome Center.
All news
Also read
Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed
Should young people with cancer receive different treatment than older patients? We suspect they do, but there’s currently not enough …
In search of the optimal treatment strategy for glioblastoma
Patients with recurrent glioblastoma have an unfavorable outlook and few treatment options. The recently launched GLOW study should change this …
The starting point – always the patient
Frank van Wijck, science journalist Ele Visser is handing over his position as chairman of Hartwig Medical Foundation’s Data Access Board …
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.